{
  "pmid": "41484570",
  "title": "Adjuvant anlotinib plus TACE in hepatocellular carcinoma with postoperative high-risk recurrence: a single-arm, multi-center, phase II study.",
  "abstract": "This study assessed the efficacy and safety of anlotinib plus transcatheter arterial chemoembolization (TACE) as adjuvant therapy in hepatocellular carcinoma (HCC) at high-risk recurrence after resection.",
  "authors": [
    "Zheng Wang",
    "Lei Zhang",
    "Xin Zheng",
    "Dong Zhang",
    "Xue Yang"
  ],
  "journal": "Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico",
  "year": "",
  "keywords": [
    "Adjuvant therapy",
    "Anlotinib",
    "Hepatocellular carcinoma",
    "High risk of recurrence after surgery",
    "TACE"
  ],
  "source": "pubmed",
  "collected_at": "2026-01-07T20:02:59.303911"
}